1
|
Lipska I, Di Bidino R, Niewada M, Nemeth B, Bochenek T, Kukla M, Więckowska B, Sobczak A, Iłowiecka K, Zemplenyi A, Martelli N, Martin T, Filiniuk O, Kosyachenko K, Sucu R, Piniazhko O, Zaliska O, Avdeyev A, Shanazarov N, von Pinoci M, Hren R. Overcoming Barriers in Hospital-Based Health Technology Assessment (HB-HTA): International Expert Panel Consensus. Healthcare (Basel) 2024; 12:889. [PMID: 38727447 PMCID: PMC11083158 DOI: 10.3390/healthcare12090889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2024] [Revised: 04/17/2024] [Accepted: 04/23/2024] [Indexed: 05/13/2024] Open
Abstract
The purpose of this article is to investigate the common facilitators and barriers associated with the implementation of hospital-based health technology assessment (HB-HTA) across diverse hospital settings in seven countries. Through a two-round Delphi study, insights were gathered from a panel of 15 HTA specialists from France, Hungary, Italy, Kazakhstan, Poland, Switzerland, and Ukraine. Experts initially conducted a comprehensive review of the HB-HTA implementation in their respective countries, identifying the barriers and facilitators through descriptive analysis. Subsequently, panel experts ranked these identified barriers and facilitators on a seven-point Likert scale. A median agreement score ≥ 6 and interquartile range (IQR) ≤ 1 was accepted as reaching a consensus. Out of the 12 statements categorized as external and internal barriers and facilitators, the expert panel reached consensus on six statements (two barriers and four facilitators). The external barrier, which achieved consensus, was the lack of the formal recognition of the role of HB-HTA in national or regional legislations. The internal barrier reaching consensus was the limited availability of human resources dedicated to HB-HTA. This qualitative study indicates that HB-HTA still has progress to make before being formally accepted and integrated across most countries, although by building on the facilitating factors we identified there may be an opportunity for the implementation of internationally developed strategies to strengthen HB-HTA practices.
Collapse
Affiliation(s)
- Iga Lipska
- Health Policy Institute, 00-819 Warsaw, Poland; (I.L.); (A.S.); (K.I.)
- Medical Department, Academy of Applied Medical and Social Sciences, 82-300 Elbląg, Poland
- Hospital-Based Health Technology Assessment Interest Group, Health Technology Assessment International, Edmonton, AB T6H 5P9, Canada; (M.K.); (R.S.)
| | - Rossella Di Bidino
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy;
- Health Graduate School of Health Economics and Management (ALTEMS), Università Cattolica Del Sacro Cuore, 00168 Rome, Italy
| | - Maciej Niewada
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 02-091 Warsaw, Poland;
| | - Bertalan Nemeth
- Syreon Research Institute, 1142 Budapest, Hungary; (B.N.); (A.Z.)
| | - Tomasz Bochenek
- Department of Nutrition and Drug Research, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, 31-126 Krakow, Poland;
| | - Monika Kukla
- Hospital-Based Health Technology Assessment Interest Group, Health Technology Assessment International, Edmonton, AB T6H 5P9, Canada; (M.K.); (R.S.)
| | - Barbara Więckowska
- Social Insurance Department, Warsaw School of Economics, 02-554 Warsaw, Poland;
| | - Alicja Sobczak
- Health Policy Institute, 00-819 Warsaw, Poland; (I.L.); (A.S.); (K.I.)
| | | | - Antal Zemplenyi
- Syreon Research Institute, 1142 Budapest, Hungary; (B.N.); (A.Z.)
- Center for Health Technology Assessment and Pharmacoeconomics Research, Faculty of Pharmacy, University of Pécs, 7624 Pécs, Hungary
| | - Nicolas Martelli
- Pharmacy Department, Georges Pompidou European Hospital, 75015 Paris, France; (N.M.); (T.M.)
- Faculty of Pharmacy, Université Paris-Saclay, GRADES, 91190 Orsay, France
| | - Tess Martin
- Pharmacy Department, Georges Pompidou European Hospital, 75015 Paris, France; (N.M.); (T.M.)
- Faculty of Pharmacy, Université Paris-Saclay, GRADES, 91190 Orsay, France
| | - Olena Filiniuk
- Safe, Affordable, and Effective Medicines for Ukrainians (SAFEMed) Activity, Management Sciences for Health, 02000 Kyiv, Ukraine;
| | - Kostyantyn Kosyachenko
- Department of Management and Economy of Pharmacy, Bogomolets National Medical University, 01601 Kyiv, Ukraine;
| | - Rabia Sucu
- Hospital-Based Health Technology Assessment Interest Group, Health Technology Assessment International, Edmonton, AB T6H 5P9, Canada; (M.K.); (R.S.)
| | - Oresta Piniazhko
- Department of Health Technology Assessment, State Expert Center, Ministry of Health of Ukraine, 01021 Kyiv, Ukraine;
- Department of Management and Economy of Pharmacy, Medicine Technology and Pharmacoeconomics, Faculty of Postgraduate Education, Danylo Halytsky Lviv National Medical University, 79010 Lviv, Ukraine;
| | - Olha Zaliska
- Department of Management and Economy of Pharmacy, Medicine Technology and Pharmacoeconomics, Faculty of Postgraduate Education, Danylo Halytsky Lviv National Medical University, 79010 Lviv, Ukraine;
| | - Andrey Avdeyev
- Medical Center Hospital of the President’s Affairs Administration of the Republic of Kazakhstan, Astana 010000, Kazakhstan; (A.A.); (N.S.)
| | - Nasrulla Shanazarov
- Medical Center Hospital of the President’s Affairs Administration of the Republic of Kazakhstan, Astana 010000, Kazakhstan; (A.A.); (N.S.)
| | - Marina von Pinoci
- Care Quality Division, Hôpitaux Universitaires de Genève, 1211 Geneva, Switzerland;
| | - Rok Hren
- Syreon Research Institute, 1142 Budapest, Hungary; (B.N.); (A.Z.)
- Institute of Mathematics, Physics, and Mechanics, 1000 Ljubljana, Slovenia
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana, Slovenia
| |
Collapse
|
4
|
Shedding light on the HTA consultancy market: Insights from Poland. Health Policy 2019; 123:1237-1243. [PMID: 31466804 DOI: 10.1016/j.healthpol.2019.08.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Revised: 07/26/2019] [Accepted: 08/12/2019] [Indexed: 11/22/2022]
Abstract
Research on health technology assessment (HTA) from a policy perspective typically examines public HTA bodies, with little attention devoted to how manufacturers develop their evidence submissions. Taking Poland as a crucial case, we explored the market of HTA consultancy firms which assist drug manufacturers in developing these submissions, called HTA reports. We reviewed 318 HTA reports from 2012 to 2015, data from the Polish National Company Registry, the content of HTA consulting firms' websites, and appraisal reports developed by the Polish HTA body. We identified HTA consultancy firms which developed 96-98% HTA reports. We found that the transparency of information about the authors of HTA reports provided by the HTA body had improved between 2012 and 2015. Six companies with market shares from 10 to 30% dominated the market. The market size was estimated to be 5-6 million EUR annually. HTA consultancies had a broad service portfolio related to preparation of HTA reports. Over 90% of HTA reports did not meet the official minimum quality requirements, and only half of the resubmissions took into account remarks made by the HTA body. Our study provides insights into the structure, evolution and role of the for-profit HTA consultancy market as a crucial part of the public HTA system. This raises important policy points about transparency and regulation at the intersection of public and private sectors in HTA.
Collapse
|
5
|
When health technology assessment is confidential and experts have no power: the case of Hungary. HEALTH ECONOMICS POLICY AND LAW 2018; 14:162-181. [PMID: 29576025 DOI: 10.1017/s1744133118000051] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Health technology assessment (HTA) is not simply a mechanistic technical exercise as it takes place within a specific institutional context. Yet, we know little about how this context influences the operation of HTA and its ability to influence policy and practice. We seek to demonstrate the importance of considering institutional context, using a case study of Hungary, a country that has pioneered HTA in Central and Eastern Europe. We conducted 26 in-depth, semi-structured interviews with public- and private-sector stakeholders. We found that while the HTA Department, the Hungarian HTA organisation, fulfilled its formal role envisaged in the legislation, its potential for supporting evidence-based decision-making was not fully realised given the low levels of transparency and stakeholder engagement. Further, the Department's practical influence throughout the reimbursement process was perceived as being constrained by the payer and policy-makers, as well as its own limited organisational capacity. There was also scepticism as to whether the current operational form of the HTA process delivered 'good value for money'. Nevertheless, it still had a positive impact on the development of a broader institutional HTA infrastructure in Hungary. Our findings highlight the importance of considering institutional context in analysing the HTA function within health systems.
Collapse
|
6
|
Wong CKH, Wu O, Cheung BMY. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions. APPLIED HEALTH ECONOMICS AND HEALTH POLICY 2018; 16:5-14. [PMID: 28702874 DOI: 10.1007/s40258-017-0339-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
The aim of this article is to describe the process, evaluation criteria, and possible outcomes of decision-making for new drugs listed in the Hong Kong Hospital Authority Drug Formulary in comparison to the health technology assessment (HTA) policy overseas. Details of decision-making processes including the new drug listing submission, Drug Advisory Committee (DAC) meeting, and procedures prior to and following the meeting, were extracted from the official Hong Kong Hospital Authority drug formulary management website and manual. Publicly-available information related to the new drug decision-making process for five HTA agencies [the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), the Australia Pharmaceutical Benefits Advisory Committee (PBAC), the Canadian Agency for Drugs and Technologies in Health (CADTH), and the New Zealand Pharmaceutical Management Agency (PHARMAC)] were reviewed and retrieved from official documents from public domains. The DAC is in charge of systemically and critically appraising new drugs before they are listed on the formulary, reviewing submitted applications, and making the decision to list the drug based on scientific evidence to which safety, efficacy, and cost-effectiveness are the primary considerations. When compared with other HTA agencies, transparency of the decision-making process of the DAC, the relevance of clinical and health economic evidence, and the lack of health economic and methodological input of submissions are the major challenges to the new-drug listing policy in Hong Kong. Despite these challenges, this review provides suggestions for the establishment of a more transparent, credible, and evidence-based decision-making process in the Hong Kong Hospital Authority Drug Formulary. Proposals for improvement in the listing of new drugs in the formulary should be a priority of healthcare reforms.
Collapse
Affiliation(s)
- Carlos King Ho Wong
- Department of Family Medicine and Primary Care, The University of Hong Kong, 3/F, Ap Lei Chau Clinic, 161 Ap Lei Chau Main Street, Ap Lei Chau, Hong Kong.
- Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, Glasgow, UK.
| | - Olivia Wu
- Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, Glasgow, UK
| | - Bernard M Y Cheung
- Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pok Fu Lam Road, Pok Fu Lam, Hong Kong
| |
Collapse
|
7
|
Transparency in practice: Evidence from ‘verification analyses’ issued by the Polish Agency for Health Technology Assessment in 2012–2015. HEALTH ECONOMICS POLICY AND LAW 2018; 14:182-204. [DOI: 10.1017/s1744133117000342] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
AbstractTransparency is recognised to be a key underpinning of the work of health technology assessment (HTA) agencies, yet it has only recently become a subject of systematic inquiry. We contribute to this research field by considering the Polish Agency for Health Technology Assessment (AHTAPol). We situate the AHTAPol in a broader context by comparing it with the National Institute for Health and Care Excellence (NICE) in England. To this end, we analyse all 332 assessment reports, called verification analyses, that the AHTAPol issued from 2012 to 2015, and a stratified sample of 22 Evidence Review Group reports published by NICE in the same period. Overall, by increasingly presenting its key conclusions in assessment reports, the AHTAPol has reached the transparency standards set out by NICE in transparency of HTA outputs. The AHTAPol is more transparent than NICE in certain aspects of the HTA process, such as providing rationales for redacting assessment reports and providing summaries of expert opinions. Nevertheless, it is less transparent in other areas of the HTA process, such as including information on expert conflicts of interest. Our findings have important implications for understanding HTA in Poland and more broadly. We use them to formulate recommendations for policymakers.
Collapse
|
8
|
Novakovic T, Martin AP, Parker M, Ferrario A, Vukovic S, Łanda K, Duba J, Dankó D, Kotsopoulos N, Godman B, Ristic J, Stefanovic D, Tesic D. The value of innovation in decision-making in health care in Central Eastern Europe - The Sixth International Conference, 2 June 2017, Belgrade, Serbia. Expert Rev Pharmacoecon Outcomes Res 2017; 17:519-521. [PMID: 28946800 DOI: 10.1080/14737167.2017.1385394] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia organised a one day international conference on the value of innovation in decision-making in health care in Central and Eastern Europe. The focus of the conference was on reimbursement decisions for medicines using health technology assessment and the use of managed entry agreements (MEAs). The objectives of this conference were firstly to discuss the challenges and opportunities with the use of MEAs in Central and Eastern European countries; secondly the role of patient registries especially with outcome based schemes, and finally new approaches to improve accessibility to new medicines including better managing their entry.
Collapse
Affiliation(s)
- Tanja Novakovic
- a Pharmacoeconomics Section , Pharmaceutical Association of Serbia , Belgrade , Serbia
| | - Antony P Martin
- b Liverpool Health Economics Centre , Liverpool University , Liverpool , UK
| | | | - Alessandra Ferrario
- d Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute , Harvard University , Boston , USA
| | - Simo Vukovic
- e Second Serbian Health Project , Ministry of Health , Belgrade , Serbia
| | - Krzysztof Łanda
- f National Center of Research & Development (NCBiR) of the Republic of Poland , Warsaw , Poland
| | | | - Dávid Dankó
- h Institute of Management , Corvinus University of Budapest , Budapest , Hungary
| | - Nikolaos Kotsopoulos
- i Global Market Access Solutions , Mooresville , NC , USA.,j School of Public Policy and Administration , University of Athens , Athens , Greece
| | - Brian Godman
- b Liverpool Health Economics Centre , Liverpool University , Liverpool , UK.,k Division of Clinical Pharmacology, Karolinska Institute , Karolinska University Hospital Huddinge , Stockholm , Sweden.,l Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences , University of Strathclyde , Glasgow , UK
| | - Jelena Ristic
- a Pharmacoeconomics Section , Pharmaceutical Association of Serbia , Belgrade , Serbia
| | - Danka Stefanovic
- a Pharmacoeconomics Section , Pharmaceutical Association of Serbia , Belgrade , Serbia
| | - Danka Tesic
- a Pharmacoeconomics Section , Pharmaceutical Association of Serbia , Belgrade , Serbia
| |
Collapse
|